Aditxt Acquisition-Partner's At-Home COVID-19 Drug Fails In Late-Stage Trial
Aditxt Acquisition-Partner's At-Home COVID-19 Drug Fails In Late-Stage Trial
Aditxt收購-合作伙伴的家用新冠肺炎藥物在後期試驗中失敗
- Aditxt Inc (NASDAQ:ADTX) has announced data from Phase 3 PRESECO trial evaluating oral Avigan/Reeqonus (favipiravir) as a potential at-home therapy for mild-to-moderate COVID-19, run by Appili Therapeutics Inc.
- The trial did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery. Additional analyses of the trial data are ongoing.
- Related Link: Aditxt Shares Surge On AiPharma Acquisition, Holder Of COVID-19 Candidate.
- The trial enrolled around 1,200 patients with mild-to-moderate COVID-19 from 38 U.S., Mexico, and Brazil study sites.
- "We are reviewing and evaluating the announced results and data and will be discussing them with AiPharma Global to determine the best course of action," stated Aditxt Co-Founder and CEO Amro Albanna.
- Price Action: ADTX shares are down 21.60% at $1.42 during the market session on the last check Friday.
- Aditxt Inc.納斯達克(Sequoia Capital：ADTX)宣佈了3期PRESECO試驗的數據，該試驗評估口服Avigan/Reeqonus(法維拉韋)作為治療輕中度新冠肺炎的潛在家庭療法，由阿普利治療公司.
- 這項試驗在持續臨牀恢復時間的主要終點上沒有統計學意義。對試驗數據的更多分析正在進行中。
- 相關鏈接：新冠肺炎候選人持有者Aipharma收購Aditxt股價飆升.
- 這項試驗招募了來自美國、墨西哥和巴西38個研究地點的約1,200名輕中度新冠肺炎患者。
- Aditxt聯合創始人兼首席執行官Amro Albanna説：“我們正在審查和評估宣佈的結果和數據，並將與Aipharma Global進行討論，以確定最佳行動方案。”
- 價格行動：在週五的最後一次檢查中，ADTX的股價在市場時段下跌了21.60%，至1.42美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。